Funded Biotechnology Startups in Lund
Lund, in Sweden's Skane Lan region, has produced a steady stream of biotechnology financings over the past two years.
Lund, in Sweden's Skane Lan region, has produced a steady stream of biotechnology financings over the past two years. The ten most recent rounds on record span April 2023 through July 2025 and range from Hamlet Pharma's $330K raise to Asgard Therapeutics' $33M round closed in March 2024 — the clear outlier in an otherwise sub-$4M cohort. Three of these deals closed in the first half of 2025 alone: Cantargia ($3M, June), SynAct Pharma ($2M, July), and Qlucore ($580K, June).
The segment skews toward therapeutics — companies like BioInvent, Cantargia, and Asgard Therapeutics sit alongside platform and tools players such as Qlucore and Cellevate, the only company in this set with a labeled Seed round ($4M, October 2023). Nearly all other rounds carry a "Series Unknown" classification, consistent with how many Swedish biotechs structure capital raises through directed share issues rather than traditional venture series.
Most recent rounds
10 shownRelated listings
Frequently asked
What is the largest recent funding round among Lund biotechs in this dataset?
Asgard Therapeutics closed the largest round at $33M in March 2024, well above the rest of the dataset. The next largest is Cellevate's $4M Seed in October 2023, followed by Cantargia and BioInvent, each at $3M.
How active has Lund biotech funding been in 2025?
Three rounds closed in the first half of 2025: SynAct Pharma raised $2M in July, Cantargia raised $3M in June, and Qlucore raised $580K in June. That pace suggests continued deal flow through mid-year.
What round types are most common in this segment?
Eight of the ten rounds are classified as Series Unknown, one is a Seed (Cellevate, $4M), and one has no round type listed (Asgard Therapeutics, $33M). Formal series labeling is sparse, which is typical for Swedish biotech raises structured as directed issues or rights offerings.
What is the typical deal size for Lund biotech raises shown here?
Excluding Asgard Therapeutics' $33M outlier, the remaining nine rounds range from $330K (Hamlet Pharma, April 2023) to $4M (Cellevate, October 2023), with most clustering between $1M and $3M.
Which companies in this list operate in therapeutics versus tools or diagnostics?
SynAct Pharma, Cantargia, Asgard Therapeutics, BioInvent, and Hamlet Pharma are therapeutics-focused. Qlucore develops bioinformatics software, Clinical Laserthermia Systems focuses on thermal ablation technology, Cellevate on cell culture scaffolds, Carbiotix on microbiome-related products, and Gedea Biotech on biotech-based treatments for vaginal conditions.
How far back does the funding activity in this dataset go?
The oldest round shown is Hamlet Pharma's $330K raise in April 2023, with Gedea Biotech and BioInvent raising in the same month. Activity then runs continuously through July 2025, covering roughly 27 months of deal history across these ten companies.
Know which startups just got funded. Every week.
Fresh funding rounds, new companies, and the sectors moving fastest — in your inbox every Monday morning.
Free. Sent every Monday. Unsubscribe anytime.